Northwest Biotherapeutics (NWBOW) Thursday announced a $5 million convertible note financing and a standby facility for up to $50 million in additional financing.
On December 19, 2024, the company had entered into a convertible promissory note agreement with YA II PN, Ltd., managed by Yorkville Advisors Global, LP.
The 13-month convertible promissory note carries a 7 percent original issue discount and no interest, with repayment due at maturity.
The note is convertible at the holder's option, at a discount to the prevailing market price, with monthly conversion limits unless the conversion price exceeds $0.315.
The company plans to use the proceeds for general corporate purposes, including advancing its lead product and in-licensed portfolios.
In addition, the company entered into a standby equity subscription agreement with Yorkville, providing the option to subscribe for up to $50 million of common shares over the next 24 months at a discount to market price.
Currently, NWBO is trading at $0.27 up by 7.61%
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.